Science1 day ago· 1 min read
Colorectal Cancer Patients Remain Cancer-Free for Nearly 3 Years After Immunotherapy Breakthrough
A UK-led trial shows that a short nine-week course of pembrolizumab immunotherapy before surgery delivers powerful results for a specific type of colorectal cancer, with patients maintaining cancer-free status for extended periods.
Major Colorectal Cancer Treatment Advance
Trial Results:
- Duration: Patients received just 9 weeks of pembrolizumab (Keytruda) before surgery
- Outcome: Remarkable cancer-free status maintained for nearly 3 years
- Location: UK-led clinical trial
Why This Matters:
- Short Treatment Window: Unlike traditional long-term therapies, this brief pre-surgical immunotherapy delivers significant benefits
- Immune Activation: Pembrolizumab works by unleashing the body's own immune system to fight cancer cells
- Paradigm Shift: Suggests immunotherapy before surgery may be more effective than previously thought
Next Steps: Results suggest this approach could become standard treatment for certain colorectal cancer subtypes, potentially improving outcomes for thousands of patients annually.